Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Author(s): Koichi Goto, MD, PhD¹; Yasushi Goto, MD, PhD²; Toshio Kubo, MD, PhD³; Kiichiro Ninomiya, MD, PhD⁴; Sang-We Kim, MD, PhD⁵; David Planchard, MD, PhD⁶; Myung-Ju Ahn, MD, PhD⁷; Egbert F. Smit, MD, PhD⁸; Adrianus Johannes de Langen, MD, PhD⁹; Maurice Pérol, MD¹⁰; Elvire Pons-Tostivint, MD, PhD¹¹; Silvia Novello, MD, PhD¹²; Hidetoshi Hayashi, MD, PhD¹³; Junichi Shimizu, MD, PhD¹⁴; Dong-Wan Kim, MD, PhD¹⁵; Chih-Hsi Kuo, MD, PhD¹⁶; James Chih-Hsin Yang, MD, PhD¹⁷; Kaline Pereira, MD, PhD¹⁸; Fu-Chih Cheng, PhD¹⁸; Ayumi Taguchi, PharmD¹⁹; Yingkai Cheng, MD, PhD¹⁸; Wenqin Feng, PhD¹⁸; Zenta Tsuchihashi, PhD¹⁸; and Pasi A. Jänne, MD, PhD²⁰

Source: DOI: 10.1200/JCO.23.01361 Journal of Clinical Oncology 41, no. 31 (November 01, 2023) 4852-4863.

Dr. Anjan Patel's Thoughts

Preliminary results of DESTINY-Lung02 show strong efficacy with trastuzumab deruxtecan (T-DXd). Overall response rate (ORR) was about 50%, with duration of response of 16.8 months. This is now FDA-approved and is an available therapy for patients with ERBB2 mutations after 1st line platinum-based chemo +/- immunotherapy. This is preferred over traditional trastuzumab or afatinib. Interestingly, some responses were seen in the ERBB2-negative patients who had over-expression by IHC. Please continue to sequence your patients and enroll in targeted therapy trials.

PURPOSE

Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2–mutant (HER2m; defined as single-nucleotide variants and exon 20 insertions) metastatic non–small-cell lung cancer (mNSCLC).

METHODS

DESTINY-Lung02, a blinded, multicenter, phase II study, investigated T-DXd 5.4 mg/kg once every 3 weeks for the first time in previously treated (platinum-containing therapy) patients with HER2m mNSCLC and further assessed T-DXd 6.4 mg/kg once every 3 weeks in this population. The primary end point was confirmed objective response rate (ORR) per RECIST v1.1 by blinded independent central review.

RESULTS

One hundred fifty-two patients were randomly assigned 2:1 to T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. As of December 23, 2022, the median duration of follow-up was 11.5 months (range, 1.1-20.6) with 5.4 mg/kg and 11.8 months (range, 0.6-21.0) with 6.4 mg/kg. Confirmed ORR was 49.0% (95% CI, 39.0 to 59.1) and 56.0% (95% CI, 41.3 to 70.0) and median duration of response was 16.8 months (95% CI, 6.4 to not estimable [NE]) and NE (95% CI, 8.3 to NE) with 5.4 and 6.4 mg/kg, respectively. Median treatment duration was 7.7 months (range, 0.7-20.8) with 5.4 mg/kg and 8.3 months (range, 0.7-20.3) with 6.4 mg/kg. Grade ≥ 3 drug-related treatment-emergent adverse events occurred in 39 of 101 (38.6%) and 29 of 50 (58.0%) patients with 5.4 and 6.4 mg/kg, respectively. 13 of 101 (12.9%) and 14 of 50 (28.0%) patients had adjudicated drug-related interstitial lung disease (2.0% grade ≥ 3 in each arm) with 5.4 and 6.4 mg/kg, respectively.

CONCLUSION

T-DXd demonstrated clinically meaningful responses at both doses. Safety profile was acceptable and generally manageable, favoring T-DXd 5.4 mg/kg.

Author Affiliations

¹National Cancer Center Hospital East, Kashiwa, Japan; ²National Cancer Center Hospital, Tokyo, Japan; ³Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan; ⁴Okayama University Hospital, Okayama, Japan; ⁵Asan Medical Center, Seoul, Republic of Korea; ⁶Gustave Roussy, Department of Medical Oncology, Thoracic Group, Villejuif, France; ⁷Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; ⁸Leiden University Medical Center, Leiden, the Netherlands; ⁹Netherlands Cancer Institute, Amsterdam, the Netherlands; ¹⁰Léon Bérard Center, Lyon, France; ¹¹Centre Hospitalier Universitaire Nantes, Nantes University, Nantes, France; ¹²Department of Oncology, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, University of Turin, Turin, Italy; ¹³Kindai University Hospital, Osaka, Japan; ¹⁴Aichi Cancer Center Hospital, Aichi, Japan; ¹⁵Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea; ¹⁶Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan; ¹⁷National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan; ¹⁸Daiichi Sankyo Inc, Basking Ridge, NJ; ¹⁹Daiichi Sankyo, Tokyo, Japan; ²⁰Dana-Farber Cancer Institute, Boston, MA

Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer

This feels like the first real crack in the "undruggable" non-G12C RAS wall in lung cancer: a pan-RAS(ON) inhibitor with responses across G12D, G12V, and other alleles in patients who had already received platinum and immunotherapy. At the 160–220 mg range (the phase 3 dose is 200 mg), patients who hadn't yet received docetaxel had a 42% response rate, median progression-free survival (PFS) of 8 mos, and median overall survival (OS) of 16 mos, which looks well ahead of what we expect from docetaxel, though that's a cross-trial comparison. The catch is tolerability: about half had grade 3 or higher events, 9 in 10 got rash, and most got diarrhea, so rash prophylaxis and proactive GI management will matter just as it does on PDAC. The randomized RASolve 301 trial against docetaxel is the one to watch before this moves into practice.

SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer

This is another nail in the anti-TIGIT coffin. In more than 500 patients with untreated PD-L1–high non–small cell lung cancer (NSCLC), adding tiragolumab to atezolizumab missed both primary endpoints, and the numerical progression-free survival (PFS) and overall survival (OS) gains never reached significance. What it did add was toxicity: twice the grade 3–4 adverse events (AEs) and more discontinuations. Together with the other failed TIGIT programs, this pretty much closes the door on chemo-free anti-TIGIT combinations in first-line NSCLC, so single-agent PD-(L)1 or chemo-IO stays the standard for these patients.

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

Progression-free survival (PFS) was higher in the Sun group vs chemotherapy, 10.3 m vs 7.5 m with HR of .65 with higher responses (58.9% vs 31.1%) diarrhea high CK and anemia were the most common side effects. The issue is that amivan was not part of treatment and compared to chemotherapy ami in addition to chemotherapy had 11m PFS also in this trial few had brain mets so no evaluation for CNS protection or treatment. But an oral agent in patients who don’t want to come to the office often.

Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer

109 patients with stage II or IIIA disease, 2-year investigator-assessed event-free survival was 92% with selpercatinib and 61% with placebo (HR for disease recurrence, progression, or death, 0.17 P<0.001). Patients with stage IB, II, or IIIA non–small-cell lung cancer (NSCLC), event-free survival at 2 years was 94% with selpercatinib and 70% with placebo. Genomic testing is expanding now for early stage NSCLC. More study in the adjuvant setting showing promise with targeted therapy.

Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer

It seems the old cliche of more drugs than patients is becoming true for most providers here. The data needs to mature further here but likely this will be another option for Anaplastic lymphoma kinase (ALK)+ non–small-cell lung cancer (NSCLC) patients in the adjuvant setting. It does look like CNS protection benefits are meaningful as well.